FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2682742413> ?p ?o ?g. }

• W2682742413 endingPage "2176" @default.
• W2682742413 startingPage "2170" @default.
• W2682742413 abstract "Patients with hepatocellular carcinoma (HCC) who respond to sorafenib have been reported to exhibit an increase in the level of des‑γ‑carboxyprothrombin (DCP) in the blood, subsequent to the initiation of sorafenib treatment. In the present study, the levels of secretion of DCP and DCP with more γ‑carboxyglutamic residues (NX‑DCP) and the effects of hypoxic conditions were examined in 13 liver cancer cell lines, and the presence of vitamin K and sorafenib, in the KYN‑2 cell line, which resulted in confirmed DCP and NX‑DCP secretion. DCP, NX‑DCP and prothrombin secretion were confirmed in 2/13 cell lines, KYN‑2 and KIM‑1. The level of secretions increased under hypoxic conditions. The addition of vitamin K suppressed cell proliferation, and DCP expression decreased to below detectable levels, however the level of prothrombin expression increased. Sorafenib treatment increased the level of apoptosis and suppressed cell proliferation, and decreased DCP and NX‑DCP. In contrast, levels of prothrombin and vascular endothelial growth factor (VEGF) expression exhibited a slight increase. When the same experiment was conducted under hypoxic conditions, DCP secretion significantly decreased in the presence of sorafenib. The level of DCP secretion increased by several fold in the sorafenib‑treated and non‑treated cells compared with the normoxic conditions. Prothrombin and VEGF values with normoxic conditions remained almost similar with hypoxic conditions. Under hypoxic conditions, NX‑DCP significantly decreased below the control values for the first 48 h subsequent to sorafenib treatment, but significantly increased at 72 h. In vivo experiments demonstrated that sorafenib inhibited angiogenesis and tumor proliferation, but the levels of DCP and NX‑DCP did not differ significantly from the controls. These findings indicate that the suppression of neovascularization by sorafenib promotes blood vessel ischemia, producing hypoxic conditions whereby vitamin K uptake and utilization efficiency is reduced." @default.
• W2682742413 created "2017-06-30" @default.
• W2682742413 creator A5021957719 @default.
• W2682742413 creator A5024527863 @default.
• W2682742413 creator A5067695489 @default.
• W2682742413 creator A5071892047 @default.
• W2682742413 creator A5081172876 @default.
• W2682742413 date "2017-06-21" @default.
• W2682742413 modified "2023-09-25" @default.
• W2682742413 title "Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line" @default.
• W2682742413 cites W1575988806 @default.
• W2682742413 cites W1838809090 @default.
• W2682742413 cites W1934927735 @default.
• W2682742413 cites W1967595077 @default.
• W2682742413 cites W1971837077 @default.
• W2682742413 cites W1983911117 @default.
• W2682742413 cites W1990623643 @default.
• W2682742413 cites W1994404990 @default.
• W2682742413 cites W1999068456 @default.
• W2682742413 cites W2012871544 @default.
• W2682742413 cites W2019224185 @default.
• W2682742413 cites W2020272106 @default.
• W2682742413 cites W2021080308 @default.
• W2682742413 cites W2032207205 @default.
• W2682742413 cites W2034215366 @default.
• W2682742413 cites W2055499437 @default.
• W2682742413 cites W2057738401 @default.
• W2682742413 cites W2060525515 @default.
• W2682742413 cites W2063574093 @default.
• W2682742413 cites W2070396671 @default.
• W2682742413 cites W2071874638 @default.
• W2682742413 cites W2072259837 @default.
• W2682742413 cites W2073384274 @default.
• W2682742413 cites W2078036558 @default.
• W2682742413 cites W2084891177 @default.
• W2682742413 cites W2087222895 @default.
• W2682742413 cites W2098744444 @default.
• W2682742413 cites W2101782801 @default.
• W2682742413 cites W2117823960 @default.
• W2682742413 cites W2140765540 @default.
• W2682742413 cites W2154493372 @default.
• W2682742413 cites W2157262448 @default.
• W2682742413 cites W2330134488 @default.
• W2682742413 cites W2412602785 @default.
• W2682742413 cites W2441354886 @default.
• W2682742413 cites W2466363821 @default.
• W2682742413 doi "https://doi.org/10.3892/ol.2017.6451" @default.
• W2682742413 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5530138" @default.
• W2682742413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28781657" @default.
• W2682742413 hasPublicationYear "2017" @default.
• W2682742413 type Work @default.
• W2682742413 sameAs 2682742413 @default.
• W2682742413 citedByCount "1" @default.
• W2682742413 countsByYear W26827424132020 @default.
• W2682742413 crossrefType "journal-article" @default.
• W2682742413 hasAuthorship W2682742413A5021957719 @default.
• W2682742413 hasAuthorship W2682742413A5024527863 @default.
• W2682742413 hasAuthorship W2682742413A5067695489 @default.
• W2682742413 hasAuthorship W2682742413A5071892047 @default.
• W2682742413 hasAuthorship W2682742413A5081172876 @default.
• W2682742413 hasBestOaLocation W26827424131 @default.
• W2682742413 hasConcept C121608353 @default.
• W2682742413 hasConcept C126322002 @default.
• W2682742413 hasConcept C134018914 @default.
• W2682742413 hasConcept C1491633281 @default.
• W2682742413 hasConcept C167734588 @default.
• W2682742413 hasConcept C185592680 @default.
• W2682742413 hasConcept C190283241 @default.
• W2682742413 hasConcept C2777025900 @default.
• W2682742413 hasConcept C2778019345 @default.
• W2682742413 hasConcept C2778695046 @default.
• W2682742413 hasConcept C2781018059 @default.
• W2682742413 hasConcept C29537977 @default.
• W2682742413 hasConcept C49039625 @default.
• W2682742413 hasConcept C54355233 @default.
• W2682742413 hasConcept C55493867 @default.
• W2682742413 hasConcept C62112901 @default.
• W2682742413 hasConcept C71924100 @default.
• W2682742413 hasConcept C81885089 @default.
• W2682742413 hasConcept C86803240 @default.
• W2682742413 hasConceptScore W2682742413C121608353 @default.
• W2682742413 hasConceptScore W2682742413C126322002 @default.
• W2682742413 hasConceptScore W2682742413C134018914 @default.
• W2682742413 hasConceptScore W2682742413C1491633281 @default.
• W2682742413 hasConceptScore W2682742413C167734588 @default.
• W2682742413 hasConceptScore W2682742413C185592680 @default.
• W2682742413 hasConceptScore W2682742413C190283241 @default.
• W2682742413 hasConceptScore W2682742413C2777025900 @default.
• W2682742413 hasConceptScore W2682742413C2778019345 @default.
• W2682742413 hasConceptScore W2682742413C2778695046 @default.
• W2682742413 hasConceptScore W2682742413C2781018059 @default.
• W2682742413 hasConceptScore W2682742413C29537977 @default.
• W2682742413 hasConceptScore W2682742413C49039625 @default.
• W2682742413 hasConceptScore W2682742413C54355233 @default.
• W2682742413 hasConceptScore W2682742413C55493867 @default.
• W2682742413 hasConceptScore W2682742413C62112901 @default.
• W2682742413 hasConceptScore W2682742413C71924100 @default.
• W2682742413 hasConceptScore W2682742413C81885089 @default.

• next